BML-277 - CAS 516480-79-8
Catalog number: B0084-300068
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Checkpoint Kinase (Chk)
BML-277 is a selective APT-competitive inhibitor of the DNA damage response signaling enzyme CHK2 ( IC50 =15 nM).
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-300068 50 mg $168 In stock
Bulk Inquiry
Off-white solid
Chk2 Inhibitor II; 2-[4-(4-chlorophenoxy)phenyl]-3H-benzimidazole-5-carboxamide;
Soluble in DMSO
Store at -20 °C
A selective APT-competitive inhibitor
Quality Standard:
Enterprise Standard
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly
Canonical SMILES:
1.The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells.
Wang FZ1, Fei HR, Cui YJ, Sun YK, Li ZM, Wang XY, Yang XY, Zhang JG, Sun BL. Apoptosis. 2014 Sep;19(9):1389-98. doi: 10.1007/s10495-014-1010-3.
Chemotherapy- or radiotherapy-induced DNA damage activates the Chk1-dependent DNA damage response (DDR) and cell cycle checkpoints to facilitate cell survival. Numerous attempts have been made to identify specific Chk1 inhibitors to enhance the efficiency of chemotherapy or radiotherapy. In this study, we investigated the molecular mechanisms underlying the antitumor activity of LY2603618, a potent and selective small molecule inhibitor of Chk1 protein kinase, in human lung cancer cells. Treatment of cancer cells with LY2603618 caused cell cycle arrest in the G2/M phase. A marked induction of DDR, including the phosphorylation of ATM, Chk2, p53 and histone H2AX, was observed after LY2603618 treatment. LY2603618 inhibited Chk1 autophosphorylation (S296 Chk1) and increased DNA damage-mediated Chk1 phosphorylation (S345 Chk1). In addition, LY2603618-treated lung cancer cells transitioned from LC3-I to LC3-II, a hallmark of autophagy. Blocking autophagy with chloroquine (CQ) further enhanced LY2603618's inhibitory effect on cell viability/proliferation.
2.The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells.
Deng S1, Yan T, Nikolova T, Fuhrmann D, Nemecek A, Gödtel-Armbrust U, Kaina B, Wojnowski L. Br J Pharmacol. 2015 May;172(9):2246-57. doi: 10.1111/bph.13046. Epub 2015 Feb 27.
BACKGROUND AND PURPOSE: The catalytic topoisomerase II inhibitor dexrazoxane has been associated not only with improved cancer patient survival but also with secondary malignancies and reduced tumour response.
3.Targeting of Chk2 as a countermeasure to dose-limiting toxicity triggered by topoisomerase-II (TOP2) poisons.
Gokare P1,2, Navaraj A2, Zhang S1,2, Motoyama N3, Sung SS4, Finnberg NK1,2. Oncotarget. 2016 Apr 18. doi: 10.18632/oncotarget.8790. [Epub ahead of print]
The DNA damage response (DDR) gene cell cycle checkpoint kinase 2 (Chk2) triggers programmed cell death and lethal radiation-induced toxicity in mice in vivo. However, it is not well established to what extent targeting of Chk2 may protect from dose-limiting toxicities (DLT) inflicted by mainstay cancer chemotherapy. We screened different classes of chemotherapy in wild type and Chk2-deficient cells. Here we show that loss of Chk2 protect from cell death in vitro and lethal toxicity in vivo following treatment with topoisomerase II (TOP2)-inhibitors whereas no such protection was observed following treatment with topoisomerase I (TOP1) inhibitors. Furthermore, through combined in silico and functional screens of the Diversity Set II (NCI/NTP) chemical library we identified the carbanilide-derivative NSC105171, also known as ptu-23, as a novel Chk2 inhibitor (Chk2i). Indeed, NSC105171 can be administered safely to mice to countermeasure etoposide-induced toxicity.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Checkpoint Kinase (Chk) Products

CAS 838823-31-7 TCS 2312

TCS 2312
(CAS: 838823-31-7)

TCS 2312 is a potent checkpoint kinase 1 (chk1) inhibitor (Ki = 0.38 nM, EC50 = 60 nM). TCS 2312 potentiates the cell killing activity of Gemcitabine in breast ...

CAS 1489389-18-5 CCT245737

(CAS: 1489389-18-5)

CCT245737 is an orally bioactive CHK1 inhibitor (IC50 of 1.4 nM), displaying >1,000-fold selectivity against CHK2 and CDK1. It potently inhibits cellular CHK1 a...

CCT 241533 dihydrochloride

CCT 241533 dihydrochloride is a potent Chk2 inhibitor (IC50 = 3 nM) displaying >63-fold selectivity for Chk1 over Chk2 and a panel of 84 other kinases. CCT 2415...

CAS 860352-01-8 AZD-7762

(CAS: 860352-01-8)

AZD-7762 is a synthetic small molecule inhibitor of checkpoint kinases (Chks) with potential chemosensitizing activity. AZD7762 binds to and inhibits Chks, whic...

CAS 66748-43-4 NSC 109555 ditosylate

NSC 109555 ditosylate
(CAS: 66748-43-4)

NSC-109555 Ditosylate is an ATP-competitive Chk2 inhibitor with IC50 value of 0.2 μM. It acts by inhibiting histone H1 phosphorylation and attenuating mitochond...

LY2606368 dihydrochloride
(CAS: 1234015-54-3)

The dihydrochloride salt form of LY2606368 which also known as prexasertib, is an inhibitor of checkpoint kinase 1 and has potential effect in antineoplastic. I...

CAS 952021-60-2 PF-477736

(CAS: 952021-60-2)

PF-477736 is a proprietary compound targeting cell cycle checkpoint kinase 1 (chk1) with potential chemopotentiation activity. Chk1 inhibitor PF-477736 inhibits...

CAS 911222-45-2 LY2603618

(CAS: 911222-45-2)

LY2603618 is a potent and selective small molecule inhibitor of Chk1 protein kinase activity in vitro (IC50=7 nM) and the first selective Chk1 inhibitor to ente...

Chemical Structure

CAS 516480-79-8 BML-277

Quick Inquiry

Verification code

Featured Items